title: Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up.
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.forename: Fabio
authors.initials: F
authors.lastname: Stagno
authors.forename: Paolo
authors.initials: P
authors.lastname: Vigneri
authors.forename: Roberto
authors.initials: R
authors.lastname: Latagliata
authors.forename: Laura
authors.initials: L
authors.lastname: Cannella
authors.forename: Vittorio
authors.initials: V
authors.lastname: Del Fabro
authors.forename: Francesco
authors.initials: F
authors.lastname: Di Raimondo
authors.forename: Giuliana
authors.initials: G
authors.lastname: Alimena
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D020732:Cytogenetic Analysis; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D053208:Kaplan-Meier Estimate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D012074:Remission Induction; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate